Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

China’s Pharmaron adds a UK drug actives plant to its network

by Rick Mullin
January 13, 2022 | A version of this story appeared in Volume 100, Issue 2

 

Pharmaron, a Beijing-based drug services firm, has acquired the Cramlington, England, site of Aesica Pharmaceuticals from Recipharm. Aesica bought the active pharmaceutical ingredient (API) facility in 2004 from BASF. Aesica was acquired by Consort Medical in 2014 and Recipharm in 2019. The Cramlington site is Pharmaron’s fifth UK operation and its first in the country for commercial API production. Pharmaron offers drug discovery and small-scale API production in Hoddesdon, England.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.